» Alexion: Ultomiris obtains Advertising and marketing Authorization within the therapy of acquired generalized myasthenia gravis MyPharma Editions
» Alexion: Ultomiris obtains Advertising and marketing Authorization within the therapy of acquired generalized myasthenia gravis MyPharma Editions Posted on Tuesday, October 4, 2022 Alexion, AstraZeneca Uncommon Illness, Pronounces European Fee Advertising and marketing Authorization for Ultomiris (ravulizumab)* as a New Therapeutic Choice for the Therapy of Grownup Sufferers with Acquired Generalized Myasthenia Gravis (GAM) …